Loading…

Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease

Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuc...

Full description

Saved in:
Bibliographic Details
Published in:AIMS neuroscience 2024, Vol.11 (3), p.312-340
Main Authors: Kumar, Anmol, Gupta, Ajay Kumar, Singh, Prashant Kumar
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 340
container_issue 3
container_start_page 312
container_title AIMS neuroscience
container_volume 11
creator Kumar, Anmol
Gupta, Ajay Kumar
Singh, Prashant Kumar
description Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.
doi_str_mv 10.3934/Neuroscience.2024020
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_60b4ed5c0b9c4b049298abd2552c7852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_60b4ed5c0b9c4b049298abd2552c7852</doaj_id><sourcerecordid>3118837181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2690-cce0c2de483c06fa5be031a439cdb3fa08cbbe86ecfc0b1ee285459bf2c454433</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhiMEolXpP0DIN7hs668k9gmhio9KVeEAZ8seT7YuiR3sZKX-ewy7rbYn2-N3Ho_1NM1bRi-EFvLyFtecCgSMgBecckk5fdGcctGLTa97_vJof9Kcl3JPKWWS953Wr5sToaVgvNOnzfY27XAkM-YyIyxhhyQNZLnDbGdclwBkSn4dsZAlkRrNkCastSVlYqMnMcX9oTxM85KmQkIkP2z-HWJJ8X0hPhS0Bd80rwY7Fjw_rGfNry-ff15929x8_3p99elmA3UcugFACtyjVAJoN9jWIRXMSqHBOzFYqsA5VB3CANQxRK5a2Wo3cJCtlEKcNdd7rk_23sw5TDY_mGSD-V9IeWtsrt8a0XTUSfRt5WiQjkrNtbLO87bl0KuWV9bHPWte3YQeMC7Zjs-gz29iuDPbtDOMSdV1TFbChwMhpz8rlsVMoQCOo42Y1mIEY0qJnilWo3IfhSq2ZBye3mHU_HNujp2bg_Pa9u54xqemR8PiL-TdruA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3118837181</pqid></control><display><type>article</type><title>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</title><source>PubMed Central</source><creator>Kumar, Anmol ; Gupta, Ajay Kumar ; Singh, Prashant Kumar</creator><creatorcontrib>Kumar, Anmol ; Gupta, Ajay Kumar ; Singh, Prashant Kumar</creatorcontrib><description>Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.</description><identifier>ISSN: 2373-7972</identifier><identifier>ISSN: 2373-8006</identifier><identifier>EISSN: 2373-7972</identifier><identifier>DOI: 10.3934/Neuroscience.2024020</identifier><identifier>PMID: 39431269</identifier><language>eng</language><publisher>United States: AIMS Press</publisher><subject>ablative surgery ; deep brain stimulation (dbs) ; dopamine precursor ; motor and non-motor symptoms ; parkinson's disease (pd) ; Review</subject><ispartof>AIMS neuroscience, 2024, Vol.11 (3), p.312-340</ispartof><rights>2024 the Author(s), licensee AIMS Press.</rights><rights>2024 the Author(s), licensee AIMS Press 2024 the Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486614/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486614/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39431269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Anmol</creatorcontrib><creatorcontrib>Gupta, Ajay Kumar</creatorcontrib><creatorcontrib>Singh, Prashant Kumar</creatorcontrib><title>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</title><title>AIMS neuroscience</title><addtitle>AIMS Neurosci</addtitle><description>Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.</description><subject>ablative surgery</subject><subject>deep brain stimulation (dbs)</subject><subject>dopamine precursor</subject><subject>motor and non-motor symptoms</subject><subject>parkinson's disease (pd)</subject><subject>Review</subject><issn>2373-7972</issn><issn>2373-8006</issn><issn>2373-7972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1v1DAQhiMEolXpP0DIN7hs668k9gmhio9KVeEAZ8seT7YuiR3sZKX-ewy7rbYn2-N3Ho_1NM1bRi-EFvLyFtecCgSMgBecckk5fdGcctGLTa97_vJof9Kcl3JPKWWS953Wr5sToaVgvNOnzfY27XAkM-YyIyxhhyQNZLnDbGdclwBkSn4dsZAlkRrNkCastSVlYqMnMcX9oTxM85KmQkIkP2z-HWJJ8X0hPhS0Bd80rwY7Fjw_rGfNry-ff15929x8_3p99elmA3UcugFACtyjVAJoN9jWIRXMSqHBOzFYqsA5VB3CANQxRK5a2Wo3cJCtlEKcNdd7rk_23sw5TDY_mGSD-V9IeWtsrt8a0XTUSfRt5WiQjkrNtbLO87bl0KuWV9bHPWte3YQeMC7Zjs-gz29iuDPbtDOMSdV1TFbChwMhpz8rlsVMoQCOo42Y1mIEY0qJnilWo3IfhSq2ZBye3mHU_HNujp2bg_Pa9u54xqemR8PiL-TdruA</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Kumar, Anmol</creator><creator>Gupta, Ajay Kumar</creator><creator>Singh, Prashant Kumar</creator><general>AIMS Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2024</creationdate><title>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</title><author>Kumar, Anmol ; Gupta, Ajay Kumar ; Singh, Prashant Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2690-cce0c2de483c06fa5be031a439cdb3fa08cbbe86ecfc0b1ee285459bf2c454433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>ablative surgery</topic><topic>deep brain stimulation (dbs)</topic><topic>dopamine precursor</topic><topic>motor and non-motor symptoms</topic><topic>parkinson's disease (pd)</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Anmol</creatorcontrib><creatorcontrib>Gupta, Ajay Kumar</creatorcontrib><creatorcontrib>Singh, Prashant Kumar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>AIMS neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Anmol</au><au>Gupta, Ajay Kumar</au><au>Singh, Prashant Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</atitle><jtitle>AIMS neuroscience</jtitle><addtitle>AIMS Neurosci</addtitle><date>2024</date><risdate>2024</risdate><volume>11</volume><issue>3</issue><spage>312</spage><epage>340</epage><pages>312-340</pages><issn>2373-7972</issn><issn>2373-8006</issn><eissn>2373-7972</eissn><abstract>Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.</abstract><cop>United States</cop><pub>AIMS Press</pub><pmid>39431269</pmid><doi>10.3934/Neuroscience.2024020</doi><tpages>29</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2373-7972
ispartof AIMS neuroscience, 2024, Vol.11 (3), p.312-340
issn 2373-7972
2373-8006
2373-7972
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_60b4ed5c0b9c4b049298abd2552c7852
source PubMed Central
subjects ablative surgery
deep brain stimulation (dbs)
dopamine precursor
motor and non-motor symptoms
parkinson's disease (pd)
Review
title Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T20%3A23%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20perspective%20of%20therapeutic%20modules%20to%20overcome%20motor%20and%20nonmotor%20symptoms%20in%20Parkinson's%20disease&rft.jtitle=AIMS%20neuroscience&rft.au=Kumar,%20Anmol&rft.date=2024&rft.volume=11&rft.issue=3&rft.spage=312&rft.epage=340&rft.pages=312-340&rft.issn=2373-7972&rft.eissn=2373-7972&rft_id=info:doi/10.3934/Neuroscience.2024020&rft_dat=%3Cproquest_doaj_%3E3118837181%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2690-cce0c2de483c06fa5be031a439cdb3fa08cbbe86ecfc0b1ee285459bf2c454433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3118837181&rft_id=info:pmid/39431269&rfr_iscdi=true